Aclidinium bromide

From Wikipedia, the free encyclopedia
  (Redirected from Aclidinium Bromide)
Jump to: navigation, search
Not to be confused with Acridinium bromide or Clidinium bromide.
Aclidinium bromide
Aclidinium bromide.svg
Systematic (IUPAC) name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
Clinical data
Trade names Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Licence data US FDA:link
Legal status
Routes Inhalational
CAS number 320345-99-1 N
ATC code R03BB05
PubChem CID 11519741
ChemSpider 9694529 N
KEGG D08837 YesY
Chemical data
Formula C26H30BrNO4S2 
Molecular mass 564.555 g/mol
 N (what is this?)  (verify)

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012[1] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[2]

Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.[3] However, it does not appear to affect the risk of death or the frequency steroids are needed.[3] It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.[3]

Aclidinium is delivered via a, multidose dry powder inhaler, the Genuair inhaler.

Brand names[edit]

It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states[4]


  1. ^ "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24. 
  2. ^ Gavaldà A, Miralpeix M, Ramos I, et al (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. Epub ahead of print. 
  3. ^ a b c Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease.". The Cochrane database of systematic reviews 9: CD010509. PMID 25234126. 
  4. ^ "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.